Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comirnaty in children (COSI BAIR)
NCT05168709Phase 4Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Murdoch Children's Research Institute. Primary endpoint: Mean change from baseline of in vitro whole blood stimulation cytokine responses to COVID-19 specific and heterologous stimulants at 84 days. Started Jan 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05168709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168709.